Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation.

BACKGROUND Cardiac death is the leading cause of mortality associated with sarcoidosis in Japan. However, the involvement of sarcoidosis infiltration often remains undetected. Recently, late gadolinium enhancement with cardiovascular MRI (LGE-CMR) imaging has been introduced for the detection of myocardial infiltrative disease, as it enables the detection of even minor myocardial damage. We investigated the incidence and prognostic value of LGE-CMR in patients with extracardiac sarcoidosis without cardiac manifestations. METHODS Sixty-one consecutive patients who met the histologic and clinical criteria for sarcoidosis, and who did not have signs or symptoms of cardiovascular involvement, were prospectively recruited. LGE-CMR was performed at the time of enrollment, and patients were classified into positive or negative late gadolinium enhancement groups based on the findings. The study end point was a composite of all-cause death, symptomatic arrhythmia, and heart failure necessitating admission. RESULTS Patients were predominantly middle aged (57 ± 15 years) and female (66%), and most had stable disease activity that did not require treatment with immunosuppressants. LGE-CMR detected cardiac involvement in eight patients (13%). Interventricular septal thinning detected by echocardiography was an independent predictor of LGE-CMR-detected cardiac involvement. During the follow-up period of 50 ± 12 months, no significant difference in adverse events was noted between patients in the LGE-CMR-positive and LGE-CMR-negative groups. CONCLUSIONS LGE-CMR detected cardiac involvement in 13% of patients with sarcoidosis without cardiac manifestation, but both patients with and without LGE had relatively low event rates. TRIAL REGISTRY Japan Primary Registries Network; No.: UMIN000001549; URL: www.umin.ac.jp.

[1]  N. Hagiwara,et al.  Late Gadolinium Enhancement in Cardiac Sarcoidosis: Characteristic Magnetic Resonance Findings and Relationship With Left Ventricular Function , 2013, Journal of thoracic imaging.

[2]  S. Neubauer,et al.  The Prognostic Value of Late Gadolinium Enhancement CMR in Nonischemic Cardiomyopathies , 2012, Current Cardiology Reports.

[3]  Amit R. Patel,et al.  Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study , 2011, European journal of heart failure.

[4]  P. Saiviroonporn,et al.  Late gadolinium enhancement from cardiac magnetic resonance in ischemic and non-ischemic cardiomyopathy. , 2011, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[5]  S. Lubitz,et al.  Primary Prevention of Sudden Cardiac Death in Silent Cardiac Sarcoidosis: Role of Programmed Ventricular Stimulation , 2011, Circulation. Arrhythmia and electrophysiology.

[6]  R. Kim,et al.  Detection of Myocardial Damage in Patients With Sarcoidosis , 2009, Circulation.

[7]  M. Friedrich,et al.  Patterns of myocardial inflammation and scarring in sarcoidosis as assessed by cardiovascular magnetic resonance , 2005, Heart.

[8]  Hyun Kim,et al.  Linear Discrepancy of the Product of Two Chains , 2005, Order.

[9]  S. Russell,et al.  Recurrence of cardiac sarcoidosis in a heart transplant recipient. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  H. Crijns,et al.  The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. , 2005, Chest.

[11]  W. Dassen,et al.  Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. , 2005, Journal of the American College of Cardiology.

[12]  C. Rochitte,et al.  Cardiac Sarcoidosis Evaluated by Delayed-Enhanced Magnetic Resonance Imaging , 2003 .

[13]  M. Isobe,et al.  Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. , 2001, The American journal of cardiology.

[14]  H. Hishida,et al.  Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. , 1999, American heart journal.

[15]  O. Sharma Cardiac and neurologic dysfunction in sarcoidosis. , 1997, Clinics in chest medicine.

[16]  A. Perry,et al.  Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. , 1995, Archives of pathology & laboratory medicine.

[17]  S. Hunt,et al.  Cardiac sarcoidosis: response to steroids and transplantation. , 1987, The Journal of heart transplantation.

[18]  Y Kasahara,et al.  Colorimetry of angiotensin-I converting enzyme activity in serum. , 1981, Clinical chemistry.

[19]  G. Hutchins,et al.  Cardiac Sarcoid: A Clinicopathologic Study of 84 Unselected Patients with Systemic Sarcoidosis , 1978, Circulation.

[20]  W. T. Longcope,et al.  A STUDY OF SARCOIDOSIS , 1952 .

[21]  Long Wt,et al.  A study of sarcoidosis; based on a combined investigation of 160 cases including 30 autopsies from The Johns Hopkins Hospital and Massachusetts General Hospital. , 1952 .